| dc.contributor.advisor | Lawler, Mark | |
| dc.contributor.author | Forde, James Christopher | |
| dc.date.accessioned | 2017-05-15T14:16:48Z | |
| dc.date.available | 2017-05-15T14:16:48Z | |
| dc.date.issued | 2010 | |
| dc.identifier.citation | James Christopher Forde, 'The role of HIF-lalpha and hypoxia in the preferential response of prostate tumours to microtubule-targeting agents', [thesis], Trinity College (Dublin, Ireland). School of Medicine. Discipline of Clinical Medicine, 2010, pp 132 | |
| dc.identifier.other | TX-1-865 | |
| dc.description.abstract | Tumour hypoxia is emerging as a common feature of prostate tumours associated with poor prognosis mainly due to their resistance to chemo- radiotherapy regimes. The efficacy of microtubule-targeting agents (MTAs) has recently been shown to be modulated by Hypoxia-Inducible-Factor-1 alpha (HIF-1α). HIF- 1α over expression has been reported to occur in almost 70% of all human tumours including prostate cancer. | |
| dc.format | 1 volume | |
| dc.language.iso | en | |
| dc.publisher | Trinity College (Dublin, Ireland). School of Medicine. Discipline of Clinical Medicine | |
| dc.relation.isversionof | http://stella.catalogue.tcd.ie/iii/encore/record/C__Rb14882831 | |
| dc.subject | Clinical Medicine, M.D. | |
| dc.subject | M.D. Trinity College Dublin | |
| dc.title | The role of HIF-lalpha and hypoxia in the preferential response of prostate tumours to microtubule-targeting agents | |
| dc.type | thesis | |
| dc.type.supercollection | thesis_dissertations | |
| dc.type.supercollection | refereed_publications | |
| dc.type.qualificationlevel | Bachelor of Science | |
| dc.type.qualificationname | Doctor of Medicine (M.D.) | |
| dc.rights.ecaccessrights | openAccess | |
| dc.format.extentpagination | pp 132 | |
| dc.description.note | TARA (Trinity’s Access to Research Archive) has a robust takedown policy. Please contact us if you have any concerns: rssadmin@tcd.ie | |
| dc.identifier.uri | http://hdl.handle.net/2262/80024 | |
